| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0092-8674(94)90189-9 |
| P698 | PubMed publication ID | 7954788 |
| P2093 | author name string | A Oliff | |
| J B Gibbs | |||
| P2860 | cites work | RETRACTED: 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity | Q35107736 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 193-198 | |
| P577 | publication date | 1994-10-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Pharmaceutical research in molecular oncology | |
| P478 | volume | 79 |
| Q37204002 | A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone |
| Q28345384 | A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission |
| Q40219887 | A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo |
| Q33308713 | An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic |
| Q30774495 | Anticancer bisquaternary heterocyclic compounds: a ras-ional design |
| Q42032204 | Cell and molecular mechanisms of pathogenesis and treatment of cancer |
| Q71985306 | Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 |
| Q33929472 | Current approaches and future strategies for pancreatic carcinoma |
| Q33859300 | Discovering novel chemotherapeutic drugs for the third millennium |
| Q28378298 | Endocrine treatment in prostate cancer |
| Q71734661 | Epidermal growth factor receptor in the vesical urothelium of paraplegic and tetraplegic patients: an immunohistochemical study |
| Q56969971 | Epistructural Re-engineering of Imatinib to Eliminate Adverse Side Effects |
| Q56969981 | Epistructure-Based Design of Drugs with Controlled Promiscuity |
| Q35196541 | Experimental animal models of pancreatic carcinogenesis and metastasis |
| Q34684154 | Exploiting molecular targets in pancreatic cancer |
| Q33670187 | Farnesyltransferase inhibitors: targeting the molecular basis of cancer |
| Q45300739 | Fluorescent oligonucleotide ligation technology for identification of ras oncogene mutations |
| Q33915513 | Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. |
| Q41037063 | Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations |
| Q33187148 | Grb2 SH2 domain-binding peptide analogs as potential anticancer agents |
| Q41442987 | Growth factors in bladder cancer |
| Q39713075 | Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). |
| Q36069009 | Identification of Phosphorylated Cyclin-Dependent Kinase 1 Associated with Colorectal Cancer Survival Using Label-Free Quantitative Analyses |
| Q74007783 | In vivo biochemistry, pharmacology, and physiology |
| Q42833424 | Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. |
| Q28289708 | Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A |
| Q36997505 | Kinase packing defects as drug targets |
| Q55019223 | Links between the Prophet Muhammad (PBUH) recommended foods and disease management: A review in the light of modern superfoods. |
| Q56970090 | Multitarget Control of Drug Impact: A Therapeutic Imperative in Cancer Systems Biology |
| Q35589627 | Nanoparticle delivery of a peptide targeting EGFR signaling |
| Q35080230 | Peptide and protein drug delivery to and into tumors: challenges and solutions |
| Q33719385 | Prospects for drug screening using the reverse two-hybrid system |
| Q71011188 | Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo |
| Q38332220 | Second site suppressor mutations of a GTPase-deficient G-protein alpha-subunit. Selective inhibition of Gbeta gamma-mediated signaling |
| Q43509024 | Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2. |
| Q36819405 | Systems biology analysis of G protein and MAP kinase signaling in yeast. |
| Q35038755 | Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics |
| Q24323252 | The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue |
| Q34241295 | The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors |
| Q41111881 | The cellular basis of metastasis |
| Q73454721 | The development of alkylphosphocholines as signal transduction inhibitors: experimental and clinical challenges |
| Q24682531 | The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function |
| Q34112975 | The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents |
| Q41140298 | Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls |
| Q52541171 | Use of G-protein fusions to monitor integral membrane protein-protein interactions in yeast. |
| Q56970152 | Wrapping-Based Re-engineering of an Anticancer Drug to Make it Safer |
Search more.